

## EMA's third public meeting: 26 March 2021

PCWP / HCPWP meeting (2 March 2021)

Nathalie Bere Public and Stakeholders Engagement Department




### **ENGAGING THE PUBLIC**

# EMA Public stakeholder meetings

#### 26 March 2021

#### **BROADCAST LIVE**



Provide an update to EU citizens about the continued assessment, approval and safety monitoring of COVID-19 vaccines, as well as their expected impact at community level.

**Listen to the public and stakeholder groups** on their needs, expectations and any concerns, so that these can be considered in the relevant regulatory processes.



#### Agenda EMA public stakeholder meeting on the approval, safety monitoring and impact of COVID-19 vaccines in the EU Chaired by Noël Wathion (EMA) Introduction 12:45 - 13:00 Joining and technical checks 13:00 - 13.05 Opening remarks Emer Cooke (EMA Executive Director) 13:05 = 13.10 Welcome and introduction Noël Wathion (EMA Deputy Executive Director) Approval, safety monitoring and impact of COVID-19 vaccines in the EU 13:10 - 14:10 Update on approved and candidate COVID-19 vaccines in the EU Marco Cavaleri (Head of Biological Health Threats and Vaccines Strategy, EMA) Vaccines safety monitoring - update on emerging data since EU Peter Arlett (Head of Data Analytics and Methods, EMA) Expected impact of COVID-19 vaccination in the European Union Edoardo Colzani (Principal Expert Vaccine-Preventable Diseases, ECDC) Transparency and publication of clinical data for COVID-19 vaccines Melanie Carr (Head of Stakeholders and Communication Division, EMA) 14:10 - 14:15 Break 15' Public session with speakers and panel experts 14:15 - 15:00 Comments and questions from the public Conclusion 15:00 - 15:15 Wrap up and end of meeting 15 Noël Wathion (EMA Deputy Executive Director)

### **ENGAGING THE PUBLIC**

# EMA Public stakeholder meeting 26 March



### **EMA** is organising this open event to:

- Give an overview of COVID-19 vaccines approved in the EU and those which are currently under review
- Provide an update of post-authorisation activities, including emerging safety data since EU authorisation of the first COVID-19 vaccines, and ongoing work to address new variants
- Provide an overview on the expected impact of COVID-19 vaccination on societies
- Update on transparency and publication of clinical data for COVID-19 vaccines
- Listen to the public and stakeholders on their needs, expectations and any concerns.



### **ENGAGING THE PUBLIC**

# EMA Public stakeholder meeting on <u>26 March</u> 2021



## **WE NEED YOU!**

Please help us raise awareness about the public meeting.

Spread the word and disseminate to your respective communities!



### Thank you – any questions?

### Further information

Contact me at Nathalie.Bere@ema.europa.eu

**Official address** Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands **Send us a question** Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000



